Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31460333 | 0.86 | HDAC1 (0.41) | HDAC1SLC34A1NR1H2ESR2MAPK1 | |
| SCHEMBL20738563 | 0.86 | HDAC1 (0.41) | HDAC1HDAC2SLC34A1NR1H2ESR2 | |
| SCHEMBL12451984 | 0.85 | HDAC1 (0.39) | HDAC1SLC34A1NR1H2ESR2MAPK1 | |
| SCHEMBL9918101 | 0.84 | HDAC1 (0.40) | HDAC1SLC34A1NR1H2ESR2MAPK1 | |
| SCHEMBL28036918 | 0.84 | HDAC1 (0.40) | HDAC1SLC34A1NR1H2ESR2MAPK1 | |
| SCHEMBL25500735 | 0.82 | HDAC1 (0.36) | HDAC1HDAC2SLC34A1NR1H2ESR2 | |
| SCHEMBL28037333 | 0.82 | NR1H2 (0.40) | HDAC1SLC34A1NR1H2ESR2MAPK1 | |
| SCHEMBL6893628 | 0.82 | NR1H2 (0.40) | HDAC1SLC34A1NR1H2ESR2MAPK1 | |
| SCHEMBL24506706 | 0.82 | KDM1A (0.50) | HDAC1HDAC2SLC34A1ESR2MAPT | |
| SCHEMBL23372983 | 0.81 | HDAC1 (0.46) | HDAC1HDAC2SLC34A1NR1H2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225479-B2 | Bicyclic inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210122748-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-04-29 | — | — | US | disclosed |
| EP-3568135-B1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | ALKERMES INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10793567-B2 | Bicyclic inhibitors of histone deacetylase | RODIN THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2018132533-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122748-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC3 | HDAC1 2/4885HDAC2 1/4885SLC34A1 2627/4885 |
| US-10793567-B2 | Bicyclic inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885SLC34A1 2288/4885 |
| US-11225479-B2 | Bicyclic inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC3 | HDAC1 2/4885HDAC2 1/4885SLC34A1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.